Perbak Capital Partners’s Idexx Laboratories IDXX Stock Holding History

Perbak Capital Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-319	Closed	-$216K	–	340
2025 Q4	$216K	Sell	319 -909	-74%	-$619K	0.07%	210
2025 Q3	$785K	Sell	1,228 -5,137	-81%	-$3.12M	0.14%	165
2025 Q2	$3.41M	Buy	+6,365	New	+$3.04M	0.77%	21
2025 Q1	–	Sell	-7,022	Closed	-$2.9M	–	206
2024 Q4	$2.9M	Buy	+7,022	New	+$3.08M	1.55%	15
2024 Q3	–	Sell	-9,950	Closed	-$4.85M	–	44
2024 Q2	$4.85M	Buy	+9,950	New	+$5M	1.43%	17

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perbak Capital Partners's IDXX Position: Q1 2026 in Review

Perbak Capital Partners sold out of Idexx Laboratories (IDXX) in Q1 2026, closing a stake of 319 shares — an estimated $216K sold.

Perbak Capital Partners first reported a position in IDXX in Q2 2024 and held it in 5 quarters. The position peaked at $4.85M in Q2 2024. 1,316 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

Perbak Capital Partners reported no remaining Idexx Laboratories position as of Q1 2026 after selling out during the quarter.
Perbak Capital Partners sold 319 Idexx Laboratories shares in Q1 2026, an estimated $216K.
Perbak Capital Partners first reported a position in Idexx Laboratories in Q2 2024 and held it in 5 quarters.
Perbak Capital Partners's Idexx Laboratories position peaked at $4.85M in Q2 2024.
1,316 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.